Is hydroxyzine recommended as a sleep aid?

Hydroxyzine is NOT Recommended for Sleep

Hydroxyzine is explicitly not recommended for the treatment of insomnia according to major clinical practice guidelines due to lack of demonstrated efficacy and safety concerns. 1

Guideline-Based Recommendations

The 2017 American Academy of Sleep Medicine (AASM) Clinical Practice Guideline clearly states that over-the-counter antihistamine sleeping aids (which includes hydroxyzine) were not recommended due to lack of demonstrated efficacy as well as safety concerns 1. This represents the highest level of evidence-based guidance available for insomnia management.

The 2020 VA/DoD guidelines similarly advised against antihistamines for chronic insomnia disorder, noting that tolerance to the sedative effects of antihistamines develops after only 3-4 days of continuous use, limiting their benefit even for short-term treatment 2. The 2019 Beers Criteria carry a strong recommendation to avoid antihistamines in older adults due to their antimuscarinic adverse effect profile 2.

Safety Concerns from FDA Labeling

The FDA label for hydroxyzine highlights several critical safety issues 3:

• QT prolongation and Torsade de Pointes have been reported, particularly in patients with pre-existing heart disease, electrolyte imbalances, or concomitant use of other QT-prolonging drugs
• Contraindicated in patients with prolonged QT interval 3
• Potentiates CNS depressants, requiring dose reduction of concomitant sedatives
• Can cause Acute Generalized Exanthematous Pustulosis (AGEP), a serious skin reaction
• Particular caution needed in elderly patients due to confusion, over-sedation, and anticholinergic effects 3

What the Research Actually Shows

While a 2023 systematic review 4 identified 5 small studies (total n=207) showing "mixed efficacy" for hydroxyzine in sleep measures, this limited evidence does not override guideline recommendations. The studies were short-term only, and the review itself concluded hydroxyzine "could be considered" only when previous therapy was ineffective, not tolerated, or contraindicated—essentially as a last resort.

One concerning case report documented a patient with cirrhosis who developed acute hepatic encephalopathy requiring cessation of hydroxyzine 5, highlighting real-world safety risks.

What TO Use Instead

First-line treatment: Cognitive Behavioral Therapy for Insomnia (CBT-I) is the standard of care 1, 2

If pharmacotherapy is needed after CBT-I failure:

• First-line medications: Short/intermediate-acting benzodiazepine receptor agonists (zolpidem, eszopiclone, zaleplon) or ramelteon 1
• Alternative option: Low-dose doxepin (3-6 mg) showed efficacy in older adults with improved safety profile compared to traditional antihistamines 2
• For patients >55 years: Prolonged-release melatonin 1

Second/third-line (with specific comorbidities): Sedating antidepressants or anticonvulsants when mood disorder or epilepsy is present 1

Common Pitfalls to Avoid

• Do not prescribe hydroxyzine simply because it's "non-controlled"—lack of DEA scheduling does not equal safety or efficacy
• Avoid in elderly patients due to anticholinergic burden and fall risk
• Screen for cardiac risk factors before considering any sedating antihistamine
• Do not expect sustained benefit beyond 3-4 days due to rapid tolerance development
• Recognize that widespread off-label use does not constitute evidence-based practice—recent data shows increasing hydroxyzine prescriptions for insomnia 6, but this trend contradicts guideline recommendations

The evidence is clear: hydroxyzine lacks the efficacy data to support its use for insomnia and carries meaningful safety risks that outweigh any potential benefits.